Navigation Links
Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
Date:4/4/2012

ead compounds in two classes of drugs, protein phosphatases and novel HDACi for which US patent were recently issued, with world-wide patent applications pending.

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto in the SEC Report on Form 10-QSB for the quarter ending September 30, 2
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
2. Lixte Biotechnology Holdings Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
3. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
4. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
5. Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004
6. Global Biotechnology Industry
7. JumpStart Invests $250,000 in Milo Biotechnology
8. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
9. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
10. Animal Biotechnology - Technologies, Markets and Companies
11. Puma Biotechnology Announces Completion of Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 ... has announced the addition of Jain PharmaBiotech,s ... Markets and Companies"  to their offering.  ... disease remains a challenge in management. With ... in the seven major markets of the ...
(Date:5/28/2015)... Research and Markets ... of Jain PharmaBiotech,s new report "Therapeutic ... to their offering.      ... deals with therapeutic drug monitoring, a multi-disciplinary ... by monitoring drug levels in the blood ...
(Date:5/28/2015)... , May 28, 2015  Quest Diagnostics Incorporated ... diagnostic information services, announced that it is scheduled to ... New York.  Steve Rusckowski , the company,s President ... five point strategy.  The presentation is scheduled for Tuesday, ... The presentation will be webcast live during the ...
(Date:5/28/2015)... 28, 2015 ... announced the addition of Jain PharmaBiotech,s ... Markets and Companies"  to their offering.  ... describes and evaluates animal biotechnology and ... pharmaceuticals as well as improvement in ...
Breaking Biology Technology:Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3Global Therapeutic Drug Monitoring Market 2015-2024 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3
... from Phase II Study Evaluating Bavituximab in Advanced ... from Phase I Study Evaluating Bavituximab in Multiple ... Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical ... treatment of cancer and serious virus infections, today ...
... The atherosclerosis vaccine,development program by AFFiRiS AG ... The respective project is being carried out in,cooperation ... of,atherosclerosis vaccination is to increase the amount of ... and thus reduce the occurrence of,harmful fatty deposits ...
... to Drive Production Efficiency and Manage Quality at New ... 27 Honeywell (NYSE: HON ) today ... a leading global manufacturer of healthcare products, to provide ... produce clinical nutrition and infusion therapy solutions. The Leading ...
Cached Biology Technology:Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 2Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 3Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting 4AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 2AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 3Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 2Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 3Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 4
(Date:5/28/2015)... 2015 Industry analyst firm n-tech Research ... titled "Markets for Self-Healing Materials: 2015-2022." According to the ... vascular systems, biomaterials, relevant shape memory materials and ... billion by 2020. The report is ... smart materials. Other recent n-tech reports have included studies ...
(Date:5/27/2015)...   Codonics (codonics.com), a global ... documentation solutions and Omnicell  (omnicell.com), a ... is pleased to announce their state of ... System® (SLS), an award-winning FDA class 2 ... Anesthesia Workstation, helps prevent medication errors, streamlines ...
(Date:5/26/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/p2kc6z/saudi_arabia ... "Saudi Arabia Biometric Systems Market Forecast and Opportunities, ... http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market in ... grow at over 22% CAGR through 2020 ... surging demand for better biometric technologies in the ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2
... The Lupus Research Institute (LRI) strategy of backing innovative ... yielded an unprecedented $30 million in large-scale funding from ... private sources, an independent progress report has determined. ... novel research grants from the 7-year-old LRIan Institute investment ...
... increase depth and breadth of coverage, applicability and usefulness ... Information Facility (GBIF) has set a goal of making ... its data portal by December 2008., GBIF calls on ... digitising and sharing their data to deepen and broaden ...
... big dividends to aging baby boomers who want to stay ... geriatric medicine at Saint Louis University, in a new book ... as we age. Living well and feeling good enough ... is priceless, says Morley, who is coauthor of The Science ...
Cached Biology News:Lupus Research Institute strategy delivers $30 million in national funding 2GBIF sets goal of mobilizing 1 billion records by end of 2008 2Eat chocolate, drink wine, add fun to life: SLU geriatrician shares secrets of staying young 2Eat chocolate, drink wine, add fun to life: SLU geriatrician shares secrets of staying young 3Eat chocolate, drink wine, add fun to life: SLU geriatrician shares secrets of staying young 4
... AmpliTaq Gold® DNA Polymerase is a ... When the chemical moiety is attached to ... set-up and the first ramp of thermal ... non-optimal annealing temperatures), the enzyme is inactive. ...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Ps-Aeruginosa (IgG) -Ab EIA Sample Size: 100 l...
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
Biology Products: